An interventional study of Transseptal ViMAC in Mitral Annular Calcification, Mitral Stenosis and Mitral Regurgitation, sponsored by Mayra Guerrero. Recruiting at 17 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-13.
Sponsored by Mayra Guerrero · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Mitral Valve Stenosis with a site in United States — 3 open to participants now, 5 under way, none of them phase 3. Mitral Valve Stenosis · United States.
Among the 11 studies in Mitral Valve Stenosis with a site in United States, this one is one of 2 that started in 2021, is one of 8 with no phase, and was the 7th registered.
63 studies on the registry are indexed under Mitral Valve Stenosis; 23 are open to participants now.
Browse Mitral Valve Stenosis studies →3 of the 11 studies in Mitral Valve Stenosis with a site in United States are open now. Recruiting first, the newest first:
Abbott Medical Devices · Sites in United States
Ages 18+
Abbott Medical Devices · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 17 Mitral Valve Stenosis studies recruiting now, 12 (71%) set no upper age limit and none (0%) stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 2 started in 2021.
This study's planned enrollment of 210 is above the median of 66 across 35 interventional studies indexed under Mitral Valve Stenosis.
Median enrollment 210 across the 9 interventional studies, 752 across the 2 observational. Of the 6 that completed or were terminated, 5 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 11 have an industry lead sponsor. The 8 most frequent:
Mayra Guerrero is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Mayra Guerrero has 1 study filed under Mitral Valve Stenosis — fewer than ten, so there is no comparison to draw.
1 of the studies in Mitral Valve Stenosis with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04408430Mayra GuerreroThe MITRAL II Pivotal Trial (Mitral Implantation of TRAnscatheter vaLves). | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies in Mitral Valve Stenosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A prospective multicenter study enrolling high surgical risk patients with severe mitral annular calcification (MAC) and symptomatic mitral valve dysfunction (severe stenosis, ≥ moderate to severe regurgitation, or mixed ≥ moderate stenosis and ≥ regurgitation). There are 2 Arms in this study: 1) "Transseptal (TS) Valve-in-MAC" (ViMAC) Arm, and 2) Natural History of Disease Registry (NHDR) for patients treated with medical treatment only (which includes patients who meet inclusion criteria but can't be treated with transeptal ViMAC due to the presence of anatomical exclusion criteria or other exclusion criteria) and have not had other procedures that may impact outcomes (i.e., alcohol septal ablation or radiofrequency ablation). The study also includes a Registry of Permanently Unassigned" for subjects who undergo preemptive septal ablation procedures (alcohol or radiofrequency) in anticipation of continuing onto ViMAC arm, but are not accepted in the ViMAC Study arm or the patient chooses not to undergo ViMAC procedure.
STUDY OBJECTIVE
The purpose of this study is to establish the safety and effectiveness of the Edwards SAPIEN 3, SAPIEN 3 Ultra and SAPIEN 3 Ultra RESILIA (SAPIEN 3/Ultra/RESILIA) valves with Commander delivery system in patients with severe mitral annular calcification and symptomatic mitral valve dysfunction who are not candidates for standard mitral valve surgery.
STUDY DESIGN
A prospective multicenter study enrolling high surgical risk patients with severe mitral annular calcification (MAC) and symptomatic mitral valve dysfunction (severe stenosis, ≥ moderate to severe regurgitation, or mixed ≥ moderate stenosis and ≥ regurgitation). There are 2 arms in this study: 1) "Transseptal (TS) Valve-in-MAC (ViMAC)" arm, 2) Natural History of Disease Registry (NHDR). Patients treated with medical treatment only (which will include patients who meet inclusion criteria but can't be treated with transseptal ViMAC due to the presence of anatomical exclusion criteria or other exclusion criteria) and have not had other procedures that may impact outcomes (i.e. alcohol septal ablation, radiofrequency ablation).
Enrollment Enrollment will consist of 110 patients in the treatment arm (transseptal ViMAC) and up to 100 in the medically treated arm).
Inclusion Criteria:
All Candidates must meet the following criteria:
Exclusion Criteria for ViMAC subjects (does not apply to the Natural History of Disease Registry):
Cardiac anatomy that would preclude appropriate delivery and deployment of an Edwards SAPIEN 3/Ultra/RESILIA valve in MAC via transseptal access, including but not limited to:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
110 MAC patients treated with transseptal Valve-in-MAC.
Device: Transseptal ViMAC
100 MAC patients not eligible for transseptal ViMAC, treated with conservative management including medications.
Transseptal TMVR using balloon-expandable aortic transcatheter valves.
Also known as: ViMAC
Primary Safety Endpoint: All Cause Morality and Hospitalization for Heart Failure
A non-hierarchical composite of all-cause mortality and hospitalization for heart failure.
Time frame: 1 year.
Secondary Effectiveness Endpoint
• Stroke at 30 days and 1 year.
Time frame: 1 year
Secondary Effectiveness Endpoint
• Change from baseline in New York Heart Association Class at 1 year.
Time frame: 1 year.
Secondary Effectiveness Endpoint
• Change from baseline in distance walked measure by the 6 Minute Walk Test at 1 year.
Time frame: 1 year.
Secondary Effectiveness Endpoint
• Change from baseline in quality-of-life measure by the Kansas City Cardiomyopathy Questionnaire (KCCQ) at 1 year.
Time frame: 1 year.
Secondary Effectiveness Endpoint
• Echocardiographic assessment of degree of mitral regurgitation (central and paravalvular) at 1 year.
Time frame: 1 year.
Secondary Effectiveness Endpoint
• Significant mitral stenosis defined as mean mitral valve gradient by echo \> 10 mmHg at 1 year.
Time frame: 1 year.
Additional Endpoint: Technical Success
• Technical success at exit from the cath lab. Defined as: * Successful vascular access, delivery and retrieval of the transcatheter valve delivery system. * Deployment of a single valve. * Correct position of transcatheter valve in the mitral annulus. * Adequate performance of the prosthetic heart valve (MVA \> 1.5 cm2) without residual mitral regurgitation grade ≥2 (+). * No need for additional surgery or re-intervention (includes drainage of pericardial effusion). * The patient leaves the cath lab alive.
Time frame: Immediately after the intervention procedure.
Additional Endpoint: Procedural Success
• Procedural Success at 30 days. Defined as: * Device success at 30 days. * No device/procedure related SAE's including: death, stroke, MI or coronary ischemia requiring PCI or CABG, stage 2 or 3 AKI including dialysis, life threatening bleeding, major vascular or access complications (arterial, venous, or TA - any event requiring additional unplanned surgical or transcatheter intervention), pericardial effusion or tamponade requiring drainage, severe hypotension, heart failure or respiratory failure requiring intravenous pressors or invasive or mechanical treatments such as ultrafiltration or hemodynamic assist devices including intra-aortic balloon pump or left ventricular assist device, or prolonged intubation for ≥48 hrs, or any valve-related dysfunction, migration, thrombosis, or other complication requiring surgery or repeat intervention.
Time frame: 30 days
Additional Endpoint: Device Success
Device success is defined as: * Stroke free survival with original valve in place. * No need for additional surgery or re-intervention related to the procedure, access or to the replacement valve. * Proper placement and intended function of the replacement valve, including * No migration, fracture, thrombosis, hemolysis or endocarditis. * No replacement valve stenosis (MV gradient \< 10 mmHg). * Replacement valve regurgitation \< 2 + (including central and paravalvular leak) and without associated hemolysis. * No increase in AI from baseline (more than 1 grade) and LVOT gradient \< 20 mmHg increase from baseline.
Time frame: 30 days.
Additional Efficacy Endpoint - NYHA Class at 30 days.
• Change from baseline in NYHA Class at 30 days.
Time frame: 30 days.
Additional Efficacy Endpoint - Distance walked in 6 MWT at 30 days
• Change from baseline in distance walked measure by the 6 MWT at 30 days.
Time frame: 30 days.
Additional Efficacy Endpoint - KCCQ at 30 days
• Change from baseline in KCCQ at 30 days.
Time frame: 30 days.
Additional Efficacy Endpoint - MR severity at 30 days
• Degree of mitral regurgitation (central and paravalvular) at 30 days.
Time frame: 30 days
Additional Safety Endpoint - Stroke at 30 days and 1 year.
• Stroke at 30 days and 1 year.
Time frame: 30 days and 1 year.
Additional Safety Endpoint - Need for ASD Closure
• Iatrogenic ASD causing RV failure or hypoxemia or need for ASD closure at discharge and 30 days.
Time frame: 30 days.
Additional Safety Endpoint - New LVOT Gradient
• New mean LVOT gradient ≥ 20 mmHg, or ≥ 20 mmHg increase from baseline LVOT gradient at 30 days and 1 year.
Time frame: 30 days and 1 year.
Additional Efficacy Endpoint - Mitral Valve Reintervention
• Mitral Valve reintervention at 30 days and 1 year.
Time frame: 30 days and 1 year.
Additional Safety Endpoint - Hospitalizations at 1 year
• Number of hospitalizations at 1 year.
Time frame: 1 year.
Additional Efficacy Endpoint - Days Alive Out of the Hospital
• Days alive out of hospital at 1 year from index procedure (ViMAC arm) or from assignment day (Natural History Registry).
Time frame: 1 year.
Additional Safety Endpoint - Hemolysis
• Hemolysis at 30 days and 1 year.
Time frame: 30 days and 1 year.
Additional Safety Endpoint - Endocarditis
• Endocarditis at 30 days and 1 year.
Time frame: 30 days and 1 year.
Additional Safety Endpoint - Blood Transfusion
• Blood transfusion at 30 days and 1 year.
Time frame: 30 days and 1 year.
Additional Safety Endpoint - New Pacemaker Requirement
• New pacemaker requirement at 30 days and 1 year.
Time frame: 30 days and 1 year.
Additional Safety Endpoint - New Aortic Valve Insufficiency
• New aortic valve insufficiency at 30 days and 1 year.
Time frame: 30 days and 1 year.
Additional Safety Endpoint - Acute Kidney Injury
• Acute kidney injury (MVARC) at 30 days and 1 year.
Time frame: 30 days and 1 year.
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Plan to share: No
Started Mar 2021 (actual). Primary completion is estimated for Dec 2026, 69 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Mayra Guerrero